A PYMNTS Company

FTC approves Valeant asset sales for Sanofi and Johnson & Johnson deals

By  |  February 22, 2012

With a 4-0 vote, the FTC has approved final consent orders remedying the anticompetitive effects of Valeant Pharmaceuticals’ proposed acquisitions of Sanofi and Johnson & Johnson’s dermatalogy businesses. For the Sanofi deal, Valeant has sold to Mylan Pharmaceuticals the manufacturing and marketing rights to products treating acne and actinic keratosis. For the Johnson & Johnson deal, Valeant has sold to Spear Pharmaceuticals the rights to an anti-wrinkle pharmaceutical product.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The orders settle charges of Section 7 Clayton Act and Section 5 FTC Act violations.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Source: FTC Press Release

     

    Related content: Consumer Protection Economics at the FTC